Do we understand our data? Evaluating comprehension and usefulness of statistical methods for continuous outcomes in meta-analyses Furqaan Sadiq 1, Reem.

Slides:



Advertisements
Similar presentations
Katrina Abuabara, MD, MA1 Esther E Freeman MD, PhD2;
Advertisements

Study Size Planning for Observational Comparative Effectiveness Research Prepared for: Agency for Healthcare Research and Quality (AHRQ)
Donald T. Simeon Caribbean Health Research Council
 Residents report using different modes of communication with LEP patients depending on the clinical encounter.  Variation in professional interpreter.
Effect Size and Meta-Analysis
15 de Abril de A Meta-Analysis is a review in which bias has been reduced by the systematic identification, appraisal, synthesis and statistical.
Practical Meta-Analysis -- D. B. Wilson
By Dr. Ahmed Mostafa Assist. Prof. of anesthesia & I.C.U. Evidence-based medicine.
Critical Appraisal of an Article by Dr. I. Selvaraj B. SC. ,M. B. B. S
® Introduction Mental Health Predictors of Pain and Function in Patients with Chronic Low Back Pain Olivia D. Lara, K. Ashok Kumar MD FRCS Sandra Burge,
Are the results valid? Was the validity of the included studies appraised?
Condom Use Questions as Predictors of Urogenital Gonorrhea Adrianne M. Williams, MD, Philana Liang, PA-C, MPH, Renee M. Gindi, MPH, Khalil G. Ghanem, MD,
Addressing missing participant data in systematic reviews: Part I – Dichotomous outcomes Elie Akl, Shanil Ebrahim, Bradley Johnston, Pablo Alonso, Matthias.
® From Bad to Worse: Comorbidities and Chronic Lower Back Pain Margaret Cecere JD, Richard Young MD, Sandra Burge PhD The University of Texas Health Science.
Evidence-Based Medicine 3 More Knowledge and Skills for Critical Reading Karen E. Schetzina, MD, MPH.
Chapter Nine Copyright © 2006 McGraw-Hill/Irwin Sampling: Theory, Designs and Issues in Marketing Research.
© 2002 Prentice-Hall, Inc.Chap 6-1 Statistics for Managers using Microsoft Excel 3 rd Edition Chapter 6 Confidence Interval Estimation.
© 2003 Prentice-Hall, Inc.Chap 6-1 Business Statistics: A First Course (3 rd Edition) Chapter 6 Sampling Distributions and Confidence Interval Estimation.
Research Skills Basic understanding of P values and Confidence limits CHE Level 5 March 2014 Sian Moss.
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins Chapter 2 Evidence-Based Nursing: Translating Research Evidence Into Practice.
Core Outcome Domains for Eczema – Results of a Delphi Consensus Project Introduction Eczema is a chronic, relapsing, inflammatory skin disorder that affects.
Chapter 7: Data for Decisions Lesson Plan Sampling Bad Sampling Methods Simple Random Samples Cautions About Sample Surveys Experiments Thinking About.
IntroductionDiscussion  Academic, mental health, behavioral, and social deficits in student adjustment are major causes of college attrition rates. 1.
EVIDENCE ABOUT DIAGNOSTIC TESTS Min H. Huang, PT, PhD, NCS.
Systematic Reviews By Jonathan Tsun & Ilona Blee.
Biostatistics Class 6 Hypothesis Testing: One-Sample Inference 2/29/2000.
® Introduction Changes in Opioid Use for Chronic Low Back Pain: One-Year Followup Roy X. Luo, Tamara Armstrong, PsyD, Sandra K. Burge, PhD The University.
Name:Shanil Ebrahim, MSc, MSc, PhD Departments of Clinical Epidemiology & Biostatistics, and Anesthesia McMaster University, Hamilton, Canada Stanford.
The Campbell Collaborationwww.campbellcollaboration.org C2 Training: May 9 – 10, 2011 Introduction to meta-analysis.
Learning Objectives Explain the role of sampling in the research process Distinguish between probability and nonprobability sampling Understand the factors.
1 Risk Assessment Tests Marina Kondratovich, Ph.D. OIVD/CDRH/FDA March 9, 2011 Molecular and Clinical Genetics Panel for Direct-to-Consumer (DTC) Genetic.
Understanding Medical Articles and Reports Linda Vincent, MPH UCSF Breast SPORE Advocate September 24,
Measuring associations between exposures and outcomes
Levels of evidence and Interpretation of a systematic review
® Changes in Opioid Use Over One Year in Patients with Chronic Low Back Pain Alejandra Garza, Gerald Kizerian, PhD, Sandra Burge, PhD The University of.
Evaluating the Medical Evidence ​ A TOOLKIT FOR THE INTERPRETING THE EFFECTIVENESS OF INTERVENTIONS Niteesh Choudhy, M.D., Ph.D.
Assessing Responsiveness of Health Measurements Ian McDowell, INTA, Santiago, March 20, 2001.
Results Providers (n=20) were more willing to share patient data when: Sharing with universities vs. private firms and non-government organizations No.
Evaluation Requirements for MSP and Characteristics of Designs to Estimate Impacts with Confidence Ellen Bobronnikov February 16, 2011.
Compliance Original Study Design Randomised Surgical care Medical care.
© 2002 Prentice-Hall, Inc.Chap 8-1 Basic Business Statistics (8 th Edition) Chapter 8 Confidence Interval Estimation.
J. Aaron Johnson, PhD 1 and J. Paul Seale, MD 2 1 Institute of Public and Preventive Health and Department of Psychology, Georgia Regents University, Augusta,
European Patients’ Academy on Therapeutic Innovation The Purpose and Fundamentals of Statistics in Clinical Trials.
Course: Research in Biomedicine and Health III Seminar 5: Critical assessment of evidence.
Chapter 9: Introduction to the t statistic. The t Statistic The t statistic allows researchers to use sample data to test hypotheses about an unknown.
Copyright © 2013, 2009, and 2007, Pearson Education, Inc. Chapter 10 Comparing Two Groups Section 10.3 Other Ways of Comparing Means and Comparing Proportions.
GRADE Grading of Recommendations Assessment, Development and Evaluation British Association of Dermatologists April 2014.
Reaching Tobacco Treatment Providers Through Online Training INTRODUCTION  U.S. Public Health Service Guidelines recommend that health care professionals.
Estimation and Confidence Intervals Chapter 9 McGraw-Hill/Irwin Copyright © 2012 by The McGraw-Hill Companies, Inc. All rights reserved.
O Make Copies of: o Areas under the Normal Curve o Appendix B.1, page 784 o (Student’s t distribution) o Appendix B.2, page 785 o Binomial Probability.
Comparative Effectiveness Research (CER) and Patient- Centered Outcomes Research (PCOR) Presentation Developed for the Academy of Managed Care Pharmacy.
Webinar May 25th METHYLPHENIDATE FOR CHILDREN AND ADOLESCENTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
Chapter 9 Estimation and Confidence Intervals. Our Objectives Define a point estimate. Define level of confidence. Construct a confidence interval for.
IDENTIFYING FRAILTY IN SURGICAL PATIENTS Furqaan Sadiq 1, Michael S. Avidan 2, Arbi Ben Abdallah 2 1 University of Missouri – Kansas City School of Medicine,
Do Decision Aids Promote Shared Decision-Making for Prostate Cancer Screening? Alex Krist MD Steven Woolf MD MPH Robert Johnson PhD Department of Family.
Jordan J 1,2, Coates WC 1,2, Clarke S 3, Runde D 4, Fowlkes E 4, Kurth J 5, Yarris L 6 1 Harbor-UCLA Medical Center, Torrance, CA 2 David Geffen School.
Cohort Study Evaluation Irina Ibraghimova
©The McGraw-Hill Companies, Inc. 2008McGraw-Hill/Irwin Estimation and Confidence Intervals Chapter 9.
Evaluation Requirements for MSP and Characteristics of Designs to Estimate Impacts with Confidence Ellen Bobronnikov March 23, 2011.
Systematic review of Present clinical reality
PSIE Pasca Sarjana Unsri
Chapter 7 The Hierarchy of Evidence
Association between risk-of-bias assessments and results of randomized trials in Cochrane reviews: the ROBES study Jelena Savović1, Becky Turner2, David.
Interval Estimation Part II
Common problems with Cochrane skin reviews
Risk ratios 12/6/ : Risk Ratios 12/6/2018 Risk ratios StatPrimer.
EAST GRADE course 2019 Introduction to Meta-Analysis
Estimation and Confidence Intervals
Evidence Based Medicine 2019 A.Bornstein MD FACC Assistant Professor of Medicine Hofstra Northwell School of Medicine Hempstead, Long Island.
Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: A pooled analysis of the Phase 3 VOYAGE 1 and VOYAGE.
Presentation transcript:

Do we understand our data? Evaluating comprehension and usefulness of statistical methods for continuous outcomes in meta-analyses Furqaan Sadiq 1, Reem A. Mustafa 1,2, Bradley C. Johnston 2, Gordon H. Guyatt 2 1 UMKC School of Medicine, 2 McMaster University, Canada OBJECTIVE INTRODUCTION Clinicians rely on summary estimates from systematic reviews (SR) and meta- analyses for clinical decision making. Interpreting a treatment’s effects – large or small – can be difficult. When pooling results of trials, authors of SR report the differences between intervention and control groups in standard deviation units of Standardized Mean Difference (SMD). Presenting results as SMD is the longest standing and most widely used approach. SMD values 0.20 represents a small difference, 0.50 represents a moderate difference and 0.80 represents a large difference. To determine clinicians’ understanding and perceptions of 6 different approaches to the presentation of continuous outcome data in meta-analyses. The six include SMD, Minimal Important Difference Units, Natural Units, Relative Risk, Risk Difference and Ratio of Means METHODS DISCUSSION UMKC clinicians best understood continuous outcomes when presented as dichotomies (relative and absolute risk differences) and also found these presentations most useful. Presenting results as SMD, the longest standing and most widely used approach, was poorly understood and not perceived as useful. Strengths: This is one of the first studies to survey physicians about their understanding and perceived usefulness of different continuous outcome presentations. We used both perceived usefulness and percent of correct answer We surveyed both internal medicine and family medicine physicians We achieved an excellent response rate from the physicians surveyed Limitations: Data is from a single center, which may represent a biased view. However, the preliminary results from other centers support the same findings. There may have been a learning effect. However, we did not observe any systematic differences in responses based on forms with different orders. Surveys were distributed in an academic institution, so the results may not be generalized to practicing physicians outside academia. 63 clinicians responded (39 FM and 24 IM), all of which provided completed surveys (95.5% response rate) Data analysis entailed calculating proportion of participants answering correctly for small and large effects, along with number of participants who favored each approach. 95% Confidence Interval was constructed for each entity. Risk Difference was the approach best understood by clinicians, followed by the Ratio of Means and Relative Risk (Table 2). Clinicians generally found dichotomous presentation of continuous outcomes (Relative Risk; Risk Difference) very useful, and other approaches less useful (Table 3). ACKNOWLEDGEMENTS Funding: None We thank all participant clinicians who answered our survey References: Cochran Review Handbook 2011 RESULTS Table 3. Perceived Usefulness of the Presentation of Continuous Outcomes, n = 63 RESULTS Table 2. Understanding of the Presentation of Continuous Outcomes, n = 63 Survey design: Participants received paper-based, self-administered surveys presenting summary estimates of a hypothetical intervention versus placebo for chronic pain, with estimates demonstrating either a small effect or large effect for each of the 6 presentation approaches. We asked 6 questions addressing understanding and 6 questions addressing preferences. We randomized participants to size of effect and order. Participants: As part of a larger multicenter international study, we invited 66 staff, residents, and trainees in family medicine (FM) and internal medicine (IM) academic programs at University of Missouri-Kansas City (UMKC) to participate, 41 FM resident and staff and 25 IM residents. We evaluated 6 common presentation approaches found in systematic reviews and meta-analyses. (1) Standard deviation units – standardized mean difference (SMD) (2) Minimal important difference units (MID) (3) Conversion into natural units of the most commonly used instrument. (4) Conversion to relative effects, calculation of relative effects (e.g. relative risk) (5) Conversion to absolute effects, calculation of absolute effects (e.g. risk difference and the corresponding number needed to treat) (6) Ratio of means or ratio of change - ratio of means (RoM) or ratio of change (RoC) between the intervention and control groups ApproachMean (SD)(95%CI) SMD2.95 (1.43)[2.60 – 3.30] MID2.92 (1.53)[2.55 – 3.30] Natural units3.75 (1.61)[ ] Relative Risk4.16 (1.69)[ ] Risk Difference4.30 (1.73)[3.87 – 4.72] Ratio of Means3.95 (1.61)[ ] ApproachN (%) correct(95% CI) SMD16 (25.4%)(16.3% %) MID9 (14.3%)[7.71% %] Natural units10 (15.9%)[8.85% %] Relative Risk21 (33.3%)[22.9% %] Risk Difference24 (38.1%)[27.1% %] Ratio of Means22 (34.9%[24.3% %] Table 1. Demographic characteristics of respondents, n = 63 CharacteristicN(%) GenderMale Female (50.8%) (49.2%) SpecialtyInternal Medicine Family Medicine (38.1%) (61.9%) Professional statusStaff Trainee 6 57 (9.6%) (90.4%) Year graduated from medical school Before and after (4.8%) (1.6%) (19.0%) (74.6%) Training in Health Research Methods or Epidemiology Never completed a formal course Completed a formal course but no degree Have master/PhD degree in HRM (74.6%) (25.4%) (0%) 1-7 scale with higher numbers indicating higher preference